Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.
Type:
Application
Filed:
July 16, 2010
Publication date:
November 4, 2010
Inventors:
Anthony Treston, Jamshed H. Shah, Robert J. D'Amato, Kimberly A. Hunsucker, John Rougas, Barry P. Conner, Victor Pribdula, Glenn M. Swartz
Abstract: The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals. The substituents are as defined in the present claim 1.
Type:
Application
Filed:
July 12, 2010
Publication date:
November 4, 2010
Applicant:
LABORATORIOS DEL DR. ESTEVE S.A
Inventors:
Antoni TORRENS JOVER, Josep Mas Prió, Alberto Dordal Zueras, Maria Angeles Fisas Escasany, Helmut-Heinrich Buschmann
Abstract: Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
Type:
Application
Filed:
April 21, 2010
Publication date:
October 28, 2010
Applicant:
Axikin Pharmaceuticals, Inc.
Inventors:
Tai Wei Ly, Marie Chantal Siu-Ying Tran, Erik Dean Baaum
Abstract: The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines. The process involves reacting a compound of the formula (III) with 3-(phthalimido)piperidine or an enantiomer thereof where X is a leaving group selected from halogens and sulphonic ester acid residues, and R1 to R3 are as defined herein, to obtain a compound of the formula (II) and deprotecting the obtained compound of the formula (II) to obtain the product xanthines.
Type:
Grant
Filed:
November 4, 2005
Date of Patent:
October 26, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Waldemar Pfrengle, Thorsten Pachur, Thomas Nicola, Adil Duran
Abstract: 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4- and/or 7-position of the isoindoline ring and optionally further substituted in the 3-position of the 2,6-dioxopiperidine ring reduce the levels of inflammatory cytokines such as TNF? in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline.
Abstract: The present invention relates to 2-(4-oxo4H-quinazolin-3-yl) acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
Type:
Grant
Filed:
March 10, 2006
Date of Patent:
October 5, 2010
Assignee:
N.V. Organon
Inventors:
Jeffrey Letourneau, Christopher Riviello, Koc-Kan Hoc, Jui-Hsiang Chan, Michael Ohlmeyer, Patrick Jokiel, Irina Neagu, John Richard Morphy, Susan Elizabeth Napier
Abstract: Chemical agents, such as derivatives of hydroxy benzene moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
Type:
Application
Filed:
April 25, 2008
Publication date:
September 30, 2010
Applicant:
AVALON PHARMACEUTICALS
Inventors:
Norman E. Ohler, Jeffrey W. Watthey, Jeffrey Strovel, Sheela K. Chellappan
Abstract: A compound of formula (I), wherein R1 represents H, or a C1-4 alkyl group; R2 represents H, a C1-4 alkyl group, C(O)CHR4NR5R6, or C(O)W; or R1 and R2 taken together represent 1,3-propylene; R3 represents H, a C1-4 alkyl group, C(O)CHR4NR5R6, or C(O)W; or R2 and R3 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, CH2OCH2, CH2SCH2 or CH2NR7CH2, wherein R7 represents H or a C1-4 alkyl group; and when one of R2 and R3 represents H, or a C1-4 alkyl group, the other one does not represent H; and R8 represents H, or a C1-4 alkyl group.
Abstract: This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the claims and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridinone and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5 such as diabetes mellitus.
Type:
Grant
Filed:
March 24, 2008
Date of Patent:
September 21, 2010
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Konrad Bleicher, Andreas D. Christ, Rainer E. Martin, Peter Mohr
Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.
Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I), as IL-6 inhibitors, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly provides novel heterocyclic compounds of the general formula (I).
Abstract: The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXR? and/or LXR? agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.
Abstract: 4-substituted 1-amidomethylcarbonyl-piperidine compounds having motilin-agonistic properties and their acid addition salts, pharmaceutical compositions containing these compounds, processes and intermediate products for the preparation of these compounds, and methods of treatment utilizing these compounds.
Type:
Grant
Filed:
November 10, 2003
Date of Patent:
August 3, 2010
Assignee:
Solvay Pharmaceuticals GmbH
Inventors:
Daniel Jasserand, Jochen Antel, Ulf Preuschoff, Reinhard Brueckner, Holger Sann, Michael Wurl, Peter Eickelmann
Abstract: Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.
Type:
Grant
Filed:
October 7, 2005
Date of Patent:
July 13, 2010
Assignee:
Vitae Pharmaceuticals, Inc.
Inventors:
John J. Baldwin, David A. Claremon, Colin M. Tice, Salvacion Cacatian, Lawrence W. Dillard, Alexey V. Ishchenko, Jing Yuan, Zhenrong Xu, Gerard McGeehan, Wei Zhao, Robert D. Simpson, Suresh B. Singh, Patrick T. Flaherty, Jean-Pierre Wery
Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Type:
Grant
Filed:
January 5, 2007
Date of Patent:
July 13, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Prasad V. Chaturvedula, Gene M. Dubowchik, Xiang Jun J. Jiang, John E. Macor, Graham S. Poindexter, Shikha Vig
Abstract: Compounds of the formula I in which R1, R2, R3 and R4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behavior, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterized by an excess of circulating serotonin or by serotonergic hyperactivity.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
June 22, 2010
Assignee:
Merck Patent GmbH
Inventors:
Kai Schiemann, Henning Böttcher, Joachim Leibrock
Abstract: Thalidomide derivative (I) and their bases or salts are new: where R represents CHR1NR2R3, CHR1NR4C(O)CHR5NR2R3, W or CHR5NR4C(O)W, where R1, R4 and R5 represent independently each other H, C1-4 alkyl, R2 is a C1-4 alkyl, R3 is a C1-4 alkyl, or R2 and R3 together represents 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, W represents 4-, 5-, 6-, 7-, or 8-mumbered, saturated or unsaturated heterocycle. The invention also relates to processes of production thereof and the use of thereof as an active pharmaceutical ingredient.
Abstract: The present invention discloses pyrido[2,3-B]pyrazin-3(4h)-ones for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like.
Type:
Grant
Filed:
October 5, 2007
Date of Patent:
June 8, 2010
Assignee:
Gilead Palo Alto, Inc.
Inventors:
Dmitry Koltun, Jeff Zablocki, Eric Parkhill, Andrey Glushkov, Natalya Vasilevich, Timur Zilbershtein, Alexey Ivanov
Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNF? in a mammal.
Type:
Grant
Filed:
April 12, 2006
Date of Patent:
May 4, 2010
Assignee:
Celgene Corporation
Inventors:
George W. Muller, David I. Stirling, Roger Shen-Chu Chen
Abstract: The present invention relates to phenylamino-substituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.
Type:
Application
Filed:
October 31, 2007
Publication date:
April 22, 2010
Inventors:
Mónica Garcia-López, Josep Mas-Prio, Antonio Torrens-Jover
Abstract: The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Grant
Filed:
August 3, 2006
Date of Patent:
March 9, 2010
Assignee:
deCODE genetics, ehf
Inventors:
Vincent Sandanayaka, Jasbir Singh, Lei Zhao, Mark E. Gurney
Abstract: Derivatives of azabicyclo octane presented by formula (I), the method of making them, and the compositions containing the same and the uses thereof as inhibitors of dipeptidyl peptidase IV (DPP-IV), wherein the substitutes in formula (I) have the same meanings as what is mentioned in the descriptions.
Type:
Application
Filed:
October 30, 2007
Publication date:
January 21, 2010
Inventors:
Pengcho Tang, Zhigang Lin, Hejun Lü, Fuqiang Zhao, Li Li
Abstract: Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
Abstract: The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z, p and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
Type:
Application
Filed:
April 13, 2007
Publication date:
December 10, 2009
Inventors:
Akira Matsumura, Hidenori Mikamiyama, Bin Shao, Naoki Tsuno, Jiangchao Yao
Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.
Type:
Application
Filed:
June 14, 2007
Publication date:
December 10, 2009
Inventors:
John Paul Kilburn, Gita Camilla Tejlgaard Kampen, Henrik Sune Andersen
Abstract: Provided are thioxo isoindoline compounds, and pharmaceutically acceptable salts, solvates, and stereoisomers, thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Abstract: The invention relates to aryl-substituted polycyclic amines of the formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof; where the symbols and radicals are explained in the description as well as to pharmaceutical compositions and medical treatments employing these compounds.
Type:
Application
Filed:
June 23, 2009
Publication date:
October 15, 2009
Applicant:
SANOFI-AVENTIS DEUTSCHLAND GMBH
Inventors:
Lothar SCHWINK, Siegfried STENGELIN, Matthias GOSSEL, Gerhard HESSLER, Petra LENNIG
Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
Type:
Grant
Filed:
September 21, 2005
Date of Patent:
August 18, 2009
Assignee:
Celgene Corporation
Inventors:
Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
Abstract: The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.
Type:
Application
Filed:
March 2, 2007
Publication date:
August 6, 2009
Applicant:
Laboratorios Del Dr. Esteve S.A.
Inventors:
Jordi Corbera-Arjona, David Vano-Domenech, Joerg Holenz
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Application
Filed:
December 15, 2008
Publication date:
July 23, 2009
Inventors:
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller, Manohar T. Saindane, Louise M. Cameron
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Application
Filed:
January 14, 2009
Publication date:
July 9, 2009
Inventors:
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller, Manohar T. Saindane, Louise M. Cameron
Abstract: There are provided a novel 3?-fluoro-5?-hydroxythalidomide derivative and an optically active substance thereof A 3?-fluoro-5?-hydroxythalidomide derivative represented by the general formula [A]: wherein R1, R2 and R3 are each a hydrogen atom; and X is C?O, and an optically active substance thereof. As analogs of thalidomide, the 3?-fluoro-5?-hydroxythalidomide derivatives are useful in the treatment of erythema nodosum of Hansen's disease, prurigo, rheumatism, Crohn's disease, graft-versus-host disease, Behcet's disease, myeloma, aphtha ulcer and the like. Further, the 3?-fluoro-5?-hydroxythalidomide derivative is useful as a drug used for treatment of multiple myeloma, TNF-? related diseases and the like.
Abstract: Polymorphic forms of 3-(amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Application
Filed:
December 15, 2008
Publication date:
June 11, 2009
Inventors:
Markian S. Jaworski, Roger Shen-Chu Chen, George W. Muller, Manohar T. Saindane, Louise M. Cameron
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Application
Filed:
December 15, 2008
Publication date:
June 11, 2009
Inventors:
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller, Manohar T. Saindane, Louise M. Cameron
Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
Type:
Application
Filed:
September 11, 2008
Publication date:
March 12, 2009
Applicant:
Wyeth
Inventors:
Dahui Zhou, Jonathan Laird Gross, Albert Jean Robichaud
Abstract: The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Application
Filed:
July 23, 2008
Publication date:
March 5, 2009
Inventors:
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
Abstract: Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
Type:
Application
Filed:
August 12, 2008
Publication date:
March 5, 2009
Applicant:
ASTRAZENECA AB
Inventors:
Sara Beha, William Brown, Shawn Johnstone, Ziping Liu, Daniel Page, Miroslaw Tomaszewski, Zhong-Yong Wei, Shi Yi Yue
Abstract: The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent.
Abstract: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.
Abstract: The present invention is directed to certain hexahydrpyrrolidinone compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
Type:
Application
Filed:
January 19, 2007
Publication date:
February 12, 2009
Inventors:
Jianming Bao, Robert J. DeVita, Huagang Lu, Sander G. Mills, Gregori J. Morriello
Abstract: The present invention creates an indole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the generic formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is C2-C4 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is independently C1-C4 alkyl etc.; R9 is carboxy etc.; Y is a single bond etc.; M is sulfonyl etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.
Abstract: The present invention relates to piperidine derivatives of formula (I): wherein R, R1, R2, R3, R4, R5, R6, X, Y, m and n are as defined herein; and pharmaceutically acceptable salts and solvates thereof; the process for their preparation and their use in the treatment of conditions mediated by tachykinins.
Type:
Grant
Filed:
February 5, 2003
Date of Patent:
January 27, 2009
Assignee:
Glaxo Group Limited
Inventors:
Giuseppe Alvaro, Alfredo Paio, Alessandro Pontiroli, Simone Spada, Maria Elvira Tranquillini
Abstract: Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.
Type:
Application
Filed:
February 6, 2008
Publication date:
January 8, 2009
Inventors:
Peter Herold, Robert Mah, Stefan Stutz, Aleksandar Stojanovic, Vincenzo Tschinke, Nathalie Jotterand
Abstract: Provided are 4?-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Type:
Application
Filed:
March 19, 2008
Publication date:
January 1, 2009
Inventors:
Alexander L. Ruchelman, George W. Muller, Hon-Wah Man
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Grant
Filed:
September 3, 2004
Date of Patent:
December 16, 2008
Assignee:
Celgene Corporation
Inventors:
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
Abstract: Sulfonylindoline compounds of formula I, wherein R1 through R4, Y and Z have defined meanings, a process for preparation of such compounds, and the use as pharmaceutically active substances, particularly for the treatment or inhibition of neurodegeneration, cardiovascular disease, inflammatory disease, hypercholesterolemia, dyslipidemia, obesity or diabetes.
Type:
Grant
Filed:
November 30, 2007
Date of Patent:
December 16, 2008
Assignee:
Laboratoires Fournier S.A.
Inventors:
Luc Lebreton, Christine Dumas, Christine Massardier, Michel Bondoux
Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.
Type:
Grant
Filed:
August 24, 2004
Date of Patent:
November 11, 2008
Assignee:
Schering Corporation
Inventors:
Kevin X. Chen, F. George Njoroge, Weiying Yang, Bancha Vibulbhan, Viyyoor M. Girijavallabhan, Srikanth Venkatraman, Francisco Velazquez